Long-term safety of a new ablation system for paroxysmal AF
Part of Heart & circulation clinical trials.
This study tests a new system (QDOT MICRO and VISITAG SURPOINT) used during a catheter ablation procedure to treat atrial fibrillation (AF). It aims to see how safe and effective it is over the long term for people whose AF comes and goes and hasn't been controlled by medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have atrial fibrillation (AF) that causes symptoms like fluttering or racing heart, and medication hasn't helped enough.
- Your AF episodes stop on their own within 7 days (this is called paroxysmal AF).
- You are 18 years or older.
- You have not had a catheter ablation for AF before.
- You are not currently in another clinical trial for a drug or device.
- You are willing to attend all follow-up visits for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to perform a common procedure (pulmonary vein isolation) for people with paroxysmal atrial fibrillation. Instead of using the standard amount of energy for a longer time, this method uses a very high amount of energy for a very short time. This might make the procedure faster and just as safe.
This trial offers a new imaging and guidance system called VERAFEYE during catheter ablation for people with paroxysmal atrial fibrillation (a type of irregular heartbeat). It aims to see if the system helps make the procedure safer and more effective.
This study tests whether a new imaging and guidance system, VERAFEYE, can help doctors perform catheter ablation for atrial fibrillation. It is designed for people with paroxysmal or persistent AF who are already scheduled for this procedure.
This trial tests a new treatment that uses two types of energy (pulsed field and radiofrequency) to fix the heart's electrical signals in people with paroxysmal atrial fibrillation (AFib that comes and goes). It aims to be more effective and safer than standard ablation alone.
This trial tests a new catheter system to treat atrial fibrillation (AF) by creating small scars in the heart to block faulty signals. It may help people with symptoms that continue despite medication and who are scheduled for a standard ablation procedure.
This trial tests three different ways of delivering radiofrequency energy using a specific catheter (QDOT) during a first-time procedure to treat atrial fibrillation (AF), a type of irregular heartbeat. It aims to find which method works best for patients with recent or short-lasting AF episodes.
Hear when a new Paroxysmal Atrial Fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.